Fintel reports that on November 24, 2025, Guggenheim maintained coverage of Pfizer (NYSE:PFE) with a Buy recommendation.

The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio. Even if Pfizer ...

(NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

Since there's no information about Carvykti (cilta-cel) in the 10-K, I've opened Legend's Form 20-F. According to it, ...

Johnson & Johnson’s JNJ stock has risen 16.7% in the past three months. A lot of this price increase is due to strong ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Detailed price information for United Parcel Service (UPS-N) from The Globe and Mail including charting and trades.

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Health care stocks have lagged the S&P 500 in 2025 thanks in part to U.S. policy uncertainty. However, health care stocks can often be a solid defensive play in an uncertain economy. People don' ...

This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.